SCHEMBL15766144

SCHEMBL15766144

Clc1nc2c3ccccc3sc2c2ccccc12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LIMK1 P53667 1/20 0.45
▸ CDK5 Q00535 1/20 0.45
▸ CDK5R1 Q15078 1/20 0.45
▸ MAPT P10636 4/20 0.44
▸ MEN1 O00255 2/20 0.44
▸ KMT2A Q03164 2/20 0.44
▸ HTT P42858 1/20 0.44
▸ NPSR1 Q6W5P4 1/20 0.44
▸ TNKS O95271 2/20 0.42
▸ TNKS2 Q9H2K2 2/20 0.42
▸ GPR3 P46089 1/20 0.41
▸ PIM1 P11309 1/20 0.41
▸ PIM2 Q9P1W9 1/20 0.41
▸ KRAS P01116 1/20 0.41
▸ HRH4 Q9H3N8 2/20 0.40
▸ LOXL2 Q9Y4K0 1/20 0.38
▸ EGLN1 Q9GZT9 1/20 0.37
▸ EGFR P00533 1/20 0.37
▸ RAB9A P51151 1/20 0.37
▸ ATM Q13315 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18647350 0.91 GPR3 (0.42) LIMK1CDK5CDK5R1MAPTMEN1
SCHEMBL19758777 0.83 GPR3 (0.41) LIMK1CDK5CDK5R1MAPTMEN1
SCHEMBL18646817 0.83 EGLN1 (0.42) LIMK1CDK5CDK5R1MAPTMEN1
SCHEMBL15766405 0.82 BCKDK (0.39) MAPTMEN1KMT2AHTTNPSR1
SCHEMBL18646710 0.82 EGLN1 (0.39) LIMK1CDK5CDK5R1MAPTMEN1
SCHEMBL18646834 0.81 EGLN1 (0.43) LIMK1CDK5CDK5R1MAPTMEN1
SCHEMBL2534139 0.80 LIMK1 (0.44) LIMK1CDK5CDK5R1MAPTMEN1
SCHEMBL18647419 0.80 EGLN1 (0.40) LIMK1CDK5CDK5R1MAPTMEN1
SCHEMBL15766397 0.78 LIMK1 (0.45) LIMK1CDK5CDK5R1MAPTMEN1
SCHEMBL2497988 0.77 HRH4 (0.53) LIMK1CDK5CDK5R1MAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2740734-B1 HCV PROTEASE INHIBITORS SHANGHAI TANGRUN PHARMACEUTICALS CO LTD (CN) 2017-09-06 — — EP disclosed
EP-2740734-B1 HCV PROTEASE INHIBITORS SHANGHAI TANGRUN PHARMACEUTICALS CO LTD (CN) 2017-09-06 — — EP disclosed
US-8969373-B2 HCV protease inhibitors Shanghai Tangrun Pharmaceuticals Co., Ltd. (CN) 2015-03-03 — — US disclosed
US-8969373-B2 HCV protease inhibitors Shanghai Tangrun Pharmaceuticals Co., Ltd. (CN) 2015-03-03 — — US disclosed
US-8969373-B2 HCV protease inhibitors Shanghai Tangrun Pharmaceuticals Co., Ltd. (CN) 2015-03-03 — — US disclosed
US-20140163219-A1 HCV Protease Inhibitors SHANGHAI TANGRUN PHARMACEUTICALS, CO., LTD. (CN) 2014-06-12 — — US disclosed
US-20140163219-A1 HCV Protease Inhibitors SHANGHAI TANGRUN PHARMACEUTICALS, CO., LTD. (CN) 2014-06-12 — — US disclosed
US-20140163219-A1 HCV Protease Inhibitors SHANGHAI TANGRUN PHARMACEUTICALS, CO., LTD. (CN) 2014-06-12 — — US disclosed
EP-2740734-A1 HCV PROTEASE INHIBITORS Shanghai Tangrun Pharmaceuticals, Co. Ltd (CN) 2014-06-11 — — EP disclosed
EP-2740734-A1 HCV PROTEASE INHIBITORS Shanghai Tangrun Pharmaceuticals, Co. Ltd (CN) 2014-06-11 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140163219-A1 HCV Protease Inhibitors CPN1, CTRL, CTSZ LIMK1 3592/4885CDK5 1896/4885CDK5R1 779/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback